Vitamin K intake and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial
American Journal of Clinical Nutrition Jan 14, 2019
Hoyt M, et al. – In this study involving participants in the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial, researchers assessed the associations of dietary intake of phylloquinone (vitamin K-1), menaquinones (vitamin K-2), and total vitamin K with the development of prostate cancer via Cox proportional hazards regression. The participants were followed-up for a median duration of 11.8 years. From a total of 28,356 men who completed the Dietary Questionnaire (DQX) and 48,090 men who completed the Dietary History Questionnaire (DHQ), 2,978 cases (including 490 advanced cases) and 2,973 cases of prostate cancer (including 647 advanced cases) were identified, respectively. The investigators found that there was no significant association between dietary intakes of phylloquinone, menaquinones, and total vitamin K, assessed with either the DQX or DHQ, and the risk of advanced, nonadvanced, and total prostate cancer, after adjustment for confounders. Overall, in this general US population, there was no influence of vitamin K intake on the occurrence of total and advanced prostate cancer.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries